نتایج جستجو برای: glucagon

تعداد نتایج: 13032  

Journal: :The Journal of endocrinology 2015
Maureen J Charron Patricia M Vuguin

Glucagon action is transduced by a G protein-coupled receptor located in liver, kidney, intestinal smooth muscle, brain, adipose tissue, heart, pancreatic β-cells, and placenta. Genetically modified animal models have provided important clues about the role of glucagon and its receptor (Gcgr) beyond glucose control. The PubMed database was searched for articles published between 1995 and 2014 u...

2013
Rui Cheng-Xue Ana Gómez-Ruiz Nancy Antoine Laura A. Noël Hee-Young Chae Magalie A. Ravier Fabrice Chimienti Frans C. Schuit Patrick Gilon

We evaluated the role of ATP-sensitive K⁺ (K(ATP)) channels, somatostatin, and Zn²⁺ in the control of glucagon secretion from mouse islets. Switching from 1 to 7 mmol/L glucose inhibited glucagon release. Diazoxide did not reverse the glucagonostatic effect of glucose. Tolbutamide decreased glucagon secretion at 1 mmol/L glucose (G1) but stimulated it at 7 mmol/L glucose (G7). The reduced gluca...

1999
MARTIN RODBELL H. MICHIEL STEPHEN L. POHL

Studies have been made of the effects of nucleotides on binding of 1*61-glucagmm at its specitlc binding sites in plasma membranes of rat Ever. GTP and GDP, equally and at a minimal concentration of 0.05 m, stimulate the rate and degree of dissociation of bound labeled hormone, decrease uptake of glucagon by the membranes, and decrease the aflinity of the binding sites for glucagon. These effec...

Journal: :The Journal of pharmacology and experimental therapeutics 2009
Hai Yan Wei Gu Jie Yang Vivian Bi Yuqing Shen Eunkyung Lee Katherine A Winters Renée Komorowski Cheng Zhang Jennifer J Patel Dorothy Caughey Gary S Elliott Yvonne Y Lau Jin Wang Yue-Sheng Li Tom Boone Richard A Lindberg Sylvia Hu Murielle M Véniant

Antagonizing the glucagon signaling pathway represents an attractive therapeutic approach for reducing excess hepatic glucose production in patients with type 2 diabetes. Despite extensive efforts, there is currently no human therapeutic that directly inhibits the glucagon/glucagon receptor pathway. We undertook a novel approach by generating high-affinity human monoclonal antibodies (mAbs) to ...

Journal: :The Journal of clinical investigation 1977
G C Weir E S Horton T T Aoki D Slovik J Jaspan A H Rubenstein

Five patients with glucagonomas had elevated plasma levels of total glucagon immunoreactivity. Gel filtrations of these plasma samples on Bio-Gel P30 columns showed that most of the immunoreactivity eluted in the 3,500-(true glucagon) and 9,000-dalton fractions. After the administration of alpha cell effectors, changes in total glucagon immunoreactivity were seen which were accounted for primar...

2015
Andrej Košmrlj Pia Cordsen Anders Kyrsting Daniel E. Otzen Lene B. Oddershede Mogens H. Jensen

We investigate in vitro fibrillation kinetics of the hormone peptide glucagon at various concentrations using confocal microscopy and determine the glucagon fibril persistence length 60μm. At all concentrations we observe that periods of individual fibril growth are interrupted by periods of stasis. The growth probability is large at high and low concentrations and is reduced for intermediate g...

Journal: :International journal of molecular medicine 2014
Willy J Malaisse

Emphasis was recently placed on the modulation of glucagon secretion attributable to a paracrine effect of somatostatin. This review draws attention to prior findings related to such a view. The effects of nutrient secretagogues upon insulin, somatostatin and glucagon release by the perfused pancreas are first considered. Three examples of paradoxical secretory responses of insulin- and glucago...

Journal: :Frontiers in Endocrinology 2023

Introduction Blood sugar homeostasis relies largely on the action of pancreatic islet hormones, particularly insulin and glucagon. In a prototypical fashion, glucagon is released upon hypoglycemia to elevate glucose by acting liver while elevated induces secretion which leads uptake peripheral tissues. This simplified view does not consider paracrine roles two hormones modulating response α- β-...

Journal: :The Journal of clinical investigation 1983
K Kawai R H Unger

The effect of glucagon at various infusion rates on plasma levels of somatostatin-like immunoreactivity (SLI) was examined in conscious normal and chronic alloxan diabetic dogs. In normal dogs glucagon infused at 6, 36, and 120 ng/kg per min did not affect the peripheral venous plasma SLI levels. In diabetic dogs, however, peripheral venous plasma SLI levels in inferior vena cava rose significa...

Journal: :The Journal of clinical investigation 1970
R H Unger E Aguilar-Parada W A Müller A M Eisentraut

The development of a glucagon radioimmunoassay with a relatively high degree of specificity for pancreatic glucagon made possible studies of alpha cell function in healthy nondiabetic subjects and in patients with diabetes mellitus. In the former group mean fasting plasma glucagon averaged 108 mumug/ml (SEM +/-10). In 12 juvenile-type diabetics fasting glucagon averaged 110 (+/-9) and in 33 adu...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید